SYNERGY-201: SX-682 + Enzalutamide in Abiraterone-Resistant mCRPC
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC), the SYNERGY-201 Trial
Principal Investigator
Professor of Medicine
Protocol Number
IRB:
PRO00113209
NCT:
NCT06228053
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL